Navigation Links
Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
Date:8/4/2011

our ability to secure FDA approval for Linjeta™ and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel™ technology; the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the possibility that patients taking Linjeta™ may experience more injection site discomfort than they experience with competing products; unexpected data that may result from our clinical trials and our research and development activities; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended March 31, 2011.  The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.Biodel Inc.
(A Development Stage Company)
Condensed Balance Sheets
(in thousands, except share and per share amounts)September 30,June 30,20102011(unaudited)ASSETSCurrent:Cash and cash equivalents$

22,922$

41,999Restricted cash15060Marketable securities, available for sale6,001—Taxes receivable11686Other receivables119Prepaid and other assets365497Total cu
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Biodel to Raise $30 Million Through Registered Direct Offering
3. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
4. Biodel Announces Name Change for Lead Product Candidate
5. Dyadic International Reports 2011 Second Quarter Financial Results
6. Vermillion Reports Results for the Second Quarter 2011
7. ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports
8. Dendreon Reports Second Quarter 2011 Financial Results
9. Cambrex Reports Second Quarter of 2011 Results
10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
11. Gen-Probe Reports Financial Results for the Second Quarter of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... , 3.75% Convertible Senior Notes due May 1, ... per $1,000 principal amount or approximately $5.72 per share, effective ... note is adjusted in connection with the regular quarterly dividend ... stockholders who own shares of PDL on March 5, 2015, the ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... report follows the broad definition of a biomarker ... and evaluated as an indicator of normal biological ... to a therapeutic intervention. Tests based on biomarkers ...
(Date:3/4/2015)... , March 4, 2015 AcelRx ... specialty pharmaceutical company focused on the development and ... acute and breakthrough pain, today announced that it ... results after market close on Monday, March 9th, ... call at 4:30 p.m. Eastern Time (1:30 p.m. ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
Breaking Biology Technology:PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... services allow Bristol-Myers Squibb to ... focus on core biopharmaceutical business, PLANO, Texas, Dec. 10 ... services contract that,calls for EDS to deliver IT infrastructure services ... allow the company to,improve productivity so Bristol-Myers Squibb can remain ...
... LONDON, Dec. 10 Oxford Finance Corporation and ... Sterling 7.5,million senior secured loan to Astex Therapeutics ... provided to a biotechnology company in,Europe., Astex ... the largest,privately-held biotech companies in the UK, concentrating ...
... Portfolio of Technologies for Enabling Faster, Easier,Quantification of Protein Biomarkers ... ... Clinical Trials, WALTHAM, Mass., Dec. 10 ... systems for,pharmaceutical research and development, today announced the company,s,PATH(R) technology ...
Cached Biology Technology:EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 2EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 3Oxford Finance Corporation and GE Healthcare Financial Services Reaffirm Commitment to Biotech Sector in Europe 2Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry 2
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... March 2, 2015   Neurotechnology , a provider ... the SentiGaze Software Development Kit (SDK). The ... that use off-the-shelf webcams to track eye movements and ... a monitor. Heatmaps can be used for applications such ... online advertising. The SDK can also be used to ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and Markets ... addition of the "Global 2D Gesture Recognition ... The analysts forecast the Global 2D ... of 32.12% over the period 2014-2019 ... non-traditional sectors is one of the major trends ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... conducted jointly by scientists at Johns Hopkins, Yale and other ... severe anemia that kills almost half of the 2 million ... is a protein cells make in response to inflammation called ... people whose red blood cells already are infected by malaria ...
... for nearly 90 years that cancer cells commonly ... this phenomenon is not completely understood. Now, a ... Cancer Cell reveals a functional connection between carbohydrate-driven ... suggest that inhibition of a specific aspect of ...
... and the fossil record abound with examples of structures ... animals. But scientists have debated whether examples of so-called ... level of genes and proteins. , In a paper ... Jianzhi (George) Zhang presents evidence for one such instance ...
Cached Biology News:How bad is malaria anemia? It may depend on your genes 2How bad is malaria anemia? It may depend on your genes 3Researchers attack tumor cells by exploiting dependency on sugar metabolism 2Parallel evolution: Proteins do it, too 2Parallel evolution: Proteins do it, too 3
Request Info...
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
Request Info...
... containing a clone of the human Topoisomerase II ... alters the topological state of nucleic acids by ... break which generates a separate DNA helix (1,2) ... passage mechanism, the enzyme can relax negatively or ...
Biology Products: